Applying the Guidelines on Recurrent
Clostridioides difficile Infection in Special Patient Populations

Virtual Midday Symposium at the 2021 ASHP Midyear Clinical Meeting and Exhibition (Midyear registration not required)

Monday, December 6, 2021
1:00 p.m. – 2:30 p.m. ET


Available at least 24 hours before webinar.

This 1.5-hour interprofessional live activity examines recent data on Clostridioides difficile infection pharmacotherapy and uses a case-based approach to apply recent guideline recommendations to special patient populations, with a focus on those at high risk for recurrent CDI.

Learning Objectives

  • Discuss the impact of Clostridioides difficile infection (CDI), including the epidemiology and pathogenesis.
  • Explain current and emerging therapeutic strategies for the treatment of CDI that are likely to result in a sustained clinical response.
  • Apply current guideline recommendations to the treatment of patients with primary and recurrent CDI.
  • Develop an interprofessional treatment plan for CDI in special patient populations (e.g., primary CDI, recurrent CDI, severe/fulminant CDI, and CDI in the immunocompromised host).


1:00 p.m.  Welcome and Introductions
Travis J. Carlson, Pharm.D., BCIDP

1:10 p.m.  Impact of Clostridioides difficile Infection (CDI)
Carolyn D. Alonso, M.D., FIDSA

1:15 p.m.  Guideline Updates for CDI Pharmacotherapy
Travis J. Carlson, Pharm.D., BCIDP

1:45 p.m.  CDI in Special Patient Populations- Patient Scenarios and Interprofessional Treatment Plans
Carolyn D. Alonso, M.D., FIDSA

2:15 p.m.  Emerging Therapies
Carolyn D. Alonso, M.D., FIDSA

2:20 p.m.  Faculty Discussion/Questions and Answers
Travis J. Carlson, Pharm.D., BCIDP and Carolyn D. Alonso, M.D., FIDSA


Travis J. Carlson, Pharm.D., BCIDP, Activity Chair
Assistant Professor
High Point University
High Point, North Carolina

Carolyn D. Alonso, M.D., FIDSA
Director, Transplant & Immunocompromised Host ID Program
Beth Israel Deaconess Medical Center
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Target Audience

This activity was planned to meet the educational needs of pharmacists, physicians, physician assistants, and nurse practitioners who care for patients at risk for recurrent Clostridioides difficile Infection.

This activity features slide presentations, active learning, and questions/discussion with faculty. 

CPE Information

ACPE #: 0204-0000-21-423-L01-P
Activity Type: Application-based
CE Credits: 1.5 contact hours (0.15 CEUs)
Activity Fee: Free of charge

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.


CME Information

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Society of Health-System Pharmacists designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Claim CE by February 1, 2022

Claim CE (enter the CE code announced during activity and complete the evaluation).

Verify credit has posted to your ​NABP eProfile account before the February 1, 2022 deadline.

After ACPE's deadline, ASHP will no longer be able to report credits.

Join the Live Broadcast

Join the live interactive webinar using your computer or smart device. 

Watch for a confirmation email with additional instructions. 

Get the app and view system requirements